Company intelligence / Profile preview

Journey Medical Corporation

Scottsdale, Arizona, United Statesjourneymedicalcorp.com ↗

Ownership: Public · DERM
Employees: ~41
Development stage: Commercial

Overview

Journey Medical Corporation markets FDA-approved prescription pharmaceutical products for dermatological conditions. Their most recent approval is Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for treating inflammatory lesions of rosacea in adults, approved in November 2024.

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Small moleculestopical formulationsoral medications
Industry: Biotech

Drug pipeline

4 assets

glycopyrronium tosylate

Approved

3 more assets in the full pipeline.

Request access →

Partnerships

Dr. Reddy's Laboratories Ltd. (for Emrosi development)

Financials

Market cap: $205M
Total revenue: $18.5M
Enterprise value: $204.9M

Beyond the preview

Go deeper on Journey Medical Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Journey Medical Corporation.

Explore the full profile